Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM).

Trial Profile

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Imatinib (Primary) ; Dasatinib; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms STIM
  • Most Recent Events

    • 20 Jan 2017 Results published in the Journal of Clinical Oncology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top